Current trials for novel second-line agents for patients with ITP
| Agent . | Mechanism of action . |
|---|---|
| BMS-986004 (Bristol-Myers Squibb) | IV administered anti-CD40L Fc-fusion protein that targets and binds CD40L expressed on T lymphocytes, which prevents T-cell-mediated proliferation and differentiation of B cells |
| PRTX-100 (Protalex, Inc.) | IV purified Staphylococcal protein A, an immunomodulatory protein, which binds to B lymphocytes and macrophages and modulates inflammation |
| Avatrombopag (Eisai, Inc.) | Oral, nonpeptide, thrombopoietin receptor agonist52 |
| Hetrombopag Olamine (Jiangsu HengRui Medicine Co., Ltd.) | Nonpeptide, thrombopoietin receptor agonist |
| R788/Fostamatinib Disodium (Rigel Pharmaceuticals) | Oral Syk kinase inhibitor that blocks immunoglobulin G receptor signaling in macrophages and B cells53 |
| Decitabine | Demethylating agent that promotes cell differentiation and maturation |
| Agent . | Mechanism of action . |
|---|---|
| BMS-986004 (Bristol-Myers Squibb) | IV administered anti-CD40L Fc-fusion protein that targets and binds CD40L expressed on T lymphocytes, which prevents T-cell-mediated proliferation and differentiation of B cells |
| PRTX-100 (Protalex, Inc.) | IV purified Staphylococcal protein A, an immunomodulatory protein, which binds to B lymphocytes and macrophages and modulates inflammation |
| Avatrombopag (Eisai, Inc.) | Oral, nonpeptide, thrombopoietin receptor agonist52 |
| Hetrombopag Olamine (Jiangsu HengRui Medicine Co., Ltd.) | Nonpeptide, thrombopoietin receptor agonist |
| R788/Fostamatinib Disodium (Rigel Pharmaceuticals) | Oral Syk kinase inhibitor that blocks immunoglobulin G receptor signaling in macrophages and B cells53 |
| Decitabine | Demethylating agent that promotes cell differentiation and maturation |
As listed on clinicaltrials.gov August 23, 2016.